Trifocal MICS IOL

Article

Carl Zeiss is set to unveil the AT LISA tri 839MP IOL at the ESCRS this year in Milan. The AT LISA enables patients to switch between near, intermediate and far distance visions without the need for corrective spectacles.

Carl Zeiss is set to unveil the AT LISA tri 839MP IOL at the ESCRS this year in Milan.

The AT LISA enables patients to switch between near, intermediate and far distance visions without the need for corrective spectacles.

AT LISA tri provides asymmetrical light distribution between 50% far vision, 20% intermediate and 30% near vision. Light energy transmittance is increased for maintained contrast sensitivity and lower visual disturbance, resulting in significantly less halos and glare. Intermediate performance is enhanced due to the additional +1.66 diopters, compared to bifocal or convoluted trifocal IOLs.

The IOL can be used in conjunction with micro-incision cataract surgery (MICS) to lower the risk of astigmatism and reduce higher order aberrations. AT LISA tri can be safely implanted through an incision of 1.8 mm when used with the BLUEMIXS 180 injector. The anti-posterior capsular opacification (PCO) profile of the lens reinforces the effect of the square edges for effective prevention of PCO.

Booth number: S117
Website:www.meditec.zeiss.com/escrs

Please note this product may not be FDA-approved for the US.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.